This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
May 15, 2013 /PRNewswire/ -- Galectin Therapeutics (NASDAQ: GALT) will host a conference call at
9:30 A.M. Eastern Time on
Thursday, May 23, 2013, to provide an update following the Company's Annual Meeting of Shareholders. Additionally,
Peter Traber, MD, President, CEO and CMO of Galectin Therapeutics, will update the investment community on the Company's pipeline of galectin inhibitor compounds and progress in its development of treatments for liver fibrosis and cancer.
Following his presentation, Dr. Traber will answer questions from shareholders present at the meeting. Shareholders not attending the meeting may submit questions in advance for Dr. Traber's consideration; questions should be submitted via email to
IR@galectintherapeutics.com no later than
May 21, 2013.
The conference call and presentation will be webcast live over the internet and can be accessed by logging on to the Galectin Therapeutics website at
The audio portion of the call can also be accessed by dialing (888) 327-8914 (toll-free within
the United States) or (847) 944-7654 (toll, from outside
the United States). The passcode for participants is 7827311#
Please log in approximately 10 minutes before the event to ensure a timely connection.
The webcast will also be archived on the Company's website.
About Galectin Therapeutics
Galectin Therapeutics (NASDAQ: GALT) is developing promising carbohydrate-based therapies for fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer. Additional information is available at
SOURCE Galectin Therapeutics